Date: 2011-04-26
Type of information: R&D agreement
Compound:
Company: Rhenovia Pharma (France) Sodiaal-Candia (France)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Rhenovia Pharma has concluded a research-and-development contract with Sodiaal-Candia, a world leader in dairy products. The contract is aimed at identifying new avenues of research for better understanding the beneficial effects on human health of the milk components and its derivatives. The research will focus in particular on studying their nutritional and therapeutic value.
By signing a first partnership with Sodiaal - Candia, a world leader in producing milk and derivatives (annual sales $ 4 billion in 2010), Rhenovia is inaugurating its entry in the health and nutrition market. Thus, after consolidating its service offering to pharmaceutical and biotechnology companies for the optimization of their Drug Discovery & Development process, Rhenovia will now apply its breakthrough technology of modeling neuronal transmission and simulating normal and pathological processes of the central and peripheral nervous systems to better understand the impact of nutrition. In particular, Rhenovia will use its technology to determine how milk and its derivatives, could interfere with the development of neurodegenerative diseases and more generally of pathologies related to aging, and uncover new research avenues for their prevention.
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
